While the therapeutic benefits of targeting APP-processing and Aβ production are still attractive, it should be noted that AD pathology is most likely triggered only when Aβ levels exceed the normal range and that the physiological processing of APP and Aβ production may be important in maintaining normal brain functions. This evidence concerns the gene APP and Alzheimer disease.